Olema Pharmaceuticals, Inc. (NASDAQ:OLMA) Receives Average Recommendation of "Moderate Buy" from Analysts

Key Points

• Olema Pharmaceuticals (NASDAQ:OLMA) has received an average rating of "Moderate Buy" from six analysts, with five recommending a buy and one suggesting a sell.
• The average target price among analysts for Olema Pharmaceuticals is $24.00, indicating potential upside from the current trading price of $7.58.
• Institutional investors own approximately 91.78% of Olema Pharmaceuticals, highlighting strong interest and confidence in the company's stock.

Shares of Olema Pharmaceuticals, Inc. (NASDAQ:OLMA - Get Free Report) have received an average rating of "Moderate Buy" from the six ratings firms that are covering the stock, MarketBeat reports. One equities research analyst has rated the stock with a sell recommendation and five have assigned a buy recommendation to the company. The average 1 year target price among analysts that have issued ratings on the stock in the last year is $24.00.

OLMA has been the subject of a number of research reports. Citigroup raised their price objective on shares of Olema Pharmaceuticals from $20.00 to $21.00 and gave the company a "buy" rating in a report on Tuesday, August 12th. The Goldman Sachs Group cut their price objective on shares of Olema Pharmaceuticals from $20.00 to $18.00 and set a "buy" rating on the stock in a report on Wednesday, May 14th. JPMorgan Chase & Co. lifted their target price on Olema Pharmaceuticals from $28.00 to $29.00 and gave the stock an "overweight" rating in a research note on Thursday, August 14th. Zacks Research upgraded Olema Pharmaceuticals to a "strong sell" rating in a research report on Monday, August 11th. Finally, Oppenheimer reaffirmed an "outperform" rating and issued a $22.00 target price on shares of Olema Pharmaceuticals in a research note on Wednesday, September 3rd.

Olema Pharmaceuticals Stock Performance

Shares of OLMA opened at $7.58 on Tuesday. Olema Pharmaceuticals has a 12 month low of $2.86 and a 12 month high of $13.93. The company's fifty day moving average is $5.20 and its 200-day moving average is $4.68. The company has a quick ratio of 11.09, a current ratio of 11.09 and a debt-to-equity ratio of 0.01. The firm has a market cap of $520.22 million, a price-to-earnings ratio of -3.83 and a beta of 1.92.

Olema Pharmaceuticals (NASDAQ:OLMA - Get Free Report) last announced its earnings results on Monday, August 11th. The company reported ($0.51) earnings per share for the quarter, missing analysts' consensus estimates of ($0.43) by ($0.08). Equities analysts expect that Olema Pharmaceuticals will post -2.33 EPS for the current fiscal year.

Institutional Trading of Olema Pharmaceuticals

Several institutional investors and hedge funds have recently added to or reduced their stakes in OLMA. Thrivent Financial for Lutherans bought a new stake in Olema Pharmaceuticals in the 2nd quarter worth approximately $308,000. Bridgeway Capital Management LLC acquired a new stake in Olema Pharmaceuticals in the second quarter worth about $213,000. Birchview Capital LP purchased a new position in Olema Pharmaceuticals during the 2nd quarter worth approximately $571,000. Ameriprise Financial Inc. raised its position in Olema Pharmaceuticals by 193.4% during the second quarter. Ameriprise Financial Inc. now owns 1,172,863 shares of the company's stock valued at $4,996,000 after acquiring an additional 773,064 shares in the last quarter. Finally, The Manufacturers Life Insurance Company increased its position in shares of Olema Pharmaceuticals by 46.7% in the second quarter. The Manufacturers Life Insurance Company now owns 22,442 shares of the company's stock valued at $96,000 after buying an additional 7,146 shares in the last quarter. Institutional investors own 91.78% of the company's stock.

About Olema Pharmaceuticals

Olema Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapies for women's cancers. Its lead product candidate is OP-1250, an estrogen receptor (ER) antagonist and a selective ER degrader, which is in Phase 3 clinical trial for the treatment of recurrent, locally advanced, or metastatic estrogen receptor-positive, human epidermal growth factor receptor 2-negative breast cancer; and OP-1250 combine with CDK4/6 inhibitors palbociclib, ribociclib, and alpelisib in Phase 1/2 clinical trial for the treatment of recurrent, locally advanced, or metastatic estrogen receptor-positive human epidermal growth factor receptor 2-negative breast cancer, as well as develops OPERA-01 for the of ER+/HER2- advanced or metastatic breast cancer.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.